Skip to main content
SpringerLink
Log in

Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficacy and safety of gemcitabine in combination with carboplatin at standard rate or fixed dose rate infusion in patients with advanced non-small-cell lung cancer (NSCLC).

Patients and methods

In this prospective study, patients with chemonaive advanced NSCLC were randomized to receive gemcitabine at a standard rate (gemcitabine 1,200 mg/m2 over 30 min, the standard arm) or a fixed dose rate (gemcitabine 1,200 mg/m2 over 120 min, the FDR arm) on days 1 and 8 every 3 week cycle. In both treatment arms, carboplatin at AUC of 5 was administered over 4 h following gemcitabine on day 1 of each cycle.

Results

From November 2003 to June 2005, a total of 42 patients, in which 7 (17%) patients had stage IIIB disease and 35 (83%) had stage IV disease, were enrolled into this study. All patients were included in efficacy and toxicity assessment. No patient had a complete response. Seven (33%) patients in the standard arm and 10 (48%) in the FDR arm had a partial response. The median time to progression and median overall survival time in the standard arm was 5.4 months (95% CI, 3.8–7 months) and 11.5 months (95% CI, 8.2–14.8 months), respectively, while in the FDR arm was 6.5 (95% CI, 4.4–8.6 months) months, 12.0 months (95% CI, 11.3–12.7 months), respectively. The most frequently reported grade 3 or 4 hematological toxicities were thrombocytopenia (38% patients in the standard arm and 43% in the FDR arm) and neutropenia (24% in the standard arm and 33% in the FDR arm). Although hematological toxicity occurred in a little higher percent of patients in the FDR arm than in the standard arm, there were no discernible differences by statistical analysis in both treatment arms (P > 0.05). And significant nonhematologic toxicities were infrequent and tolerable in both arms. No significant difference existed also (P > 0.05).

Conclusion

In this phase II study, gemcitabine in combination with carboplatin either at standard rate or fixed dose rate infusion was clinically effective and well tolerated in patients with advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics,2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899–909

    Google Scholar 

  3. Kosmidis PA, Kalofonos C, Syrigos K et al (2005) Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 23:7000

    Google Scholar 

  4. Rudd RM, Gower NH, Spiro SG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142–153

    Article  PubMed  CAS  Google Scholar 

  5. Sederholm C, Hillerdal G, Lamberg K et al (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 23:8380–8388

    Article  PubMed  CAS  Google Scholar 

  6. Anderson H, Lund B, Bach F et al (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1821–1826

    PubMed  CAS  Google Scholar 

  7. Abratt RP, Bezwoda WR, Falkson G et al (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1535–1540

    PubMed  CAS  Google Scholar 

  8. Ma CX, Nair S, Thomas S et al (2005) Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 23:5929–5937

    Article  PubMed  CAS  Google Scholar 

  9. Giovannetti E, Mey V, Nannizzi S et al (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68:110–118

    PubMed  CAS  Google Scholar 

  10. Giovannetti E, Mey V, Danesi R et al (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10:2936–2943

    Article  PubMed  CAS  Google Scholar 

  11. Ogawa M, Hori H, Ohta T et al (2005) Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma. Clin Cancer Res 11:3485–3493

    Article  PubMed  CAS  Google Scholar 

  12. Gandhi V, Plunkett W, Du M et al (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665–673

    Article  PubMed  CAS  Google Scholar 

  13. Tempero M, Plunkett W, Haperen VR et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408

    Article  PubMed  CAS  Google Scholar 

  14. Grunewald R, Abbruzzese JL, Tarassoff P et al (1991) Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258–262

    Article  PubMed  CAS  Google Scholar 

  15. Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498

    PubMed  CAS  Google Scholar 

  16. Grunewald R, Kantarjian H, Du M et al (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413

    PubMed  CAS  Google Scholar 

  17. Furuse J, Ishii H, Okusaka T et al (2005) Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer. J Clin Oncol 35:733–738

    Google Scholar 

  18. Gelibter A, Di Cosimo S, Ruggeri EM et al (2004) Fixed dose-rate gemcitabine (GEM) infusion in advanced pancreatic (PDAC) and biliary tree (BTC) carcinoma: a phase II study. ASCO Meeting Abstracts 22:4182

    Google Scholar 

  19. Ko AH, Dito E, Schillinger B et al (2006) Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 24:379–385

    Article  PubMed  CAS  Google Scholar 

  20. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    PubMed  CAS  Google Scholar 

  21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  22. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  23. Maestu I, Gomez-Aldaravi L, Torregrosa MD et al (2003) Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42:345–54

    Article  PubMed  CAS  Google Scholar 

  24. Parente B, Barroso A, Conde S et al (2001) A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule. Semin Oncol 28(Suppl):10–4

    Article  PubMed  CAS  Google Scholar 

  25. Mazzanti P, Massacesi C, Rocchi MB et al (2003) Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41:81–9

    Article  PubMed  Google Scholar 

  26. Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41:321–31

    Article  PubMed  Google Scholar 

  27. Domine M, Casado V, Estevez LG et al (2001) Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer. Semin Oncol 28(Suppl):4–9

    PubMed  CAS  Google Scholar 

  28. Bajetta E, Stani SC, Candis DD et al (2003) Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 14:242–247

    Article  PubMed  CAS  Google Scholar 

  29. Soo RA, Lim HL, Wang LZ et al (2003) Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group Study. Cancer Chemother Pharmacol 52(2):153–158

    Article  PubMed  CAS  Google Scholar 

  30. Wang LR, Huang MZ, Xu N et al (2005) Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 6:446–450

    Article  PubMed  Google Scholar 

  31. Bhargava P, Marshall JL, Fried K et al (2001) Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 48:95–103

    Article  PubMed  CAS  Google Scholar 

  32. Kroep JR, Giaccone G, Voorn DA et al (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non–small-cell lung cancer. J Clin Oncol 17:2190–2197

    PubMed  CAS  Google Scholar 

  33. Soo RA, Wang LZ, Tham LS et al (2006) A muticentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17:1128–1133

    Article  PubMed  CAS  Google Scholar 

  34. Parker RS, Fisher JW, Florian JA et al (2005) Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations. ASCO MeetingAbstracts 23:2025

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Lin Run Wang, Guo Bing Zhang & Xiu Hua Wu

  2. Department of Clinical Pharmacology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Ming Zhu Huang

  3. Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Nong Xu

Authors
  1. Lin Run Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming Zhu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guo Bing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiu Hua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guo Bing Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, L.R., Huang, M.Z., Zhang, G.B. et al. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 60, 601–607 (2007). https://doi.org/10.1007/s00280-007-0504-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0504-x

Keywords

Search

Navigation